Psoriasis and psoriatic arthritis in African-American patients--the need to measure disease burden.

MedStar author(s):
Citation: Clinical Rheumatology. 34(10):1753-9, 2015 Oct.PMID: 25164561Institution: MedStar Washington Hospital CenterDepartment: Medicine/RheumatologyForm of publication: Journal ArticleMedline article type(s): Journal Article | Multicenter Study | Research Support, Non-U.S. Gov'tSubject headings: *African Americans | *Arthritis, Psoriatic/eh [Ethnology] | *Arthritis, Psoriatic/ep [Epidemiology] | *Psoriasis/eh [Ethnology] | *Psoriasis/ep [Epidemiology] | Academic Medical Centers | Adult | Aged | Arthritis, Psoriatic/di [Diagnosis] | Arthritis, Psoriatic/pp [Physiopathology] | Biological Products/tu [Therapeutic Use] | Cohort Studies | Comorbidity | European Continental Ancestry Group | Female | Health Status | Hospitals, Veterans | Humans | Immunosuppressive Agents/tu [Therapeutic Use] | Male | Middle Aged | Psoriasis/di [Diagnosis] | Quality of Life | Severity of Illness Index | Surveys and Questionnaires | Treatment Outcome | United States/ep [Epidemiology]Year: 2015ISSN:
  • 0770-3198
Name of journal: Clinical rheumatologyAbstract: Gaps in knowledge exist regarding the clinical characteristics of psoriatic disease in ethnic minority patients. We evaluated validated clinical disease measures of psoriasis and psoriatic arthritis in African-American and Caucasian patients. Adult outpatients with confirmed diagnoses of psoriasis and psoriatic arthritis and seen at four urban academic institutions were eligible for evaluation. Validated patient and physician-reported disease outcome parameters, quality of life measures of psoriasis and psoriatic arthritis, and frequencies of systemic immunosuppressive therapies and patient comorbidities were documented. Psoriatic arthritis was less frequent in African-Americans compared to Caucasians (30 vs. 64.5 %, respectively, p<0.001); however, African-Americans had more severe skin involvement [Psoriasis Area and Severity Index 8.4 (10.0) vs. Caucasians 5.5 (6.4), p=0.06], with greater psychological impact and impaired quality of life. Use of biologic therapies was greater in Caucasian patients (46.2 vs. 13.3 % in African-Americans, p<0.0001); yet, only one in four patients of the study cohort achieved minimal disease activity. Comorbidity was not associated with frequency of immunosuppressive drug use. In order to achieve a target of low disease activity and to reduce ethnic disparities in the care of psoriatic disease, the routine application of measures of disease status is needed.All authors: Constantinescu F, Kerr GS, Kindred C, Qaiyumi S, Richards J, Vahabzadeh-Monshie H, Whelton SFiscal year: FY2016Digital Object Identifier: Date added to catalog: 2016-09-07
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 25164561 Available 25164561

Gaps in knowledge exist regarding the clinical characteristics of psoriatic disease in ethnic minority patients. We evaluated validated clinical disease measures of psoriasis and psoriatic arthritis in African-American and Caucasian patients. Adult outpatients with confirmed diagnoses of psoriasis and psoriatic arthritis and seen at four urban academic institutions were eligible for evaluation. Validated patient and physician-reported disease outcome parameters, quality of life measures of psoriasis and psoriatic arthritis, and frequencies of systemic immunosuppressive therapies and patient comorbidities were documented. Psoriatic arthritis was less frequent in African-Americans compared to Caucasians (30 vs. 64.5 %, respectively, p<0.001); however, African-Americans had more severe skin involvement [Psoriasis Area and Severity Index 8.4 (10.0) vs. Caucasians 5.5 (6.4), p=0.06], with greater psychological impact and impaired quality of life. Use of biologic therapies was greater in Caucasian patients (46.2 vs. 13.3 % in African-Americans, p<0.0001); yet, only one in four patients of the study cohort achieved minimal disease activity. Comorbidity was not associated with frequency of immunosuppressive drug use. In order to achieve a target of low disease activity and to reduce ethnic disparities in the care of psoriatic disease, the routine application of measures of disease status is needed.

English

Powered by Koha